Stockscreener 앱 받기
4.00
1.01%
0.04
X 4 Pharmaceuticals Inc 주식(XFOR)의 최신 뉴스
Can X4 Pharmaceuticals Inc. stock deliver sustainable ROEInsider Selling Patterns & Investment Risk Management Tips - ulpravda.ru
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of “Hold” by Analysts - Defense World
Europe reviews first nose-spray patients could use for sudden PSVT - Stock Titan
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Hold" by Analysts - MarketBeat
What drives X4 Pharmaceuticals Inc 48Q0 stock priceAnalyst Upgrades & Free Powerful Profit Generation - earlytimes.in
Torrent Pharma board gives nod to Rs 12,500-crore bond issue - TradingView — Track All Markets
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Layoff Tracker: Nido Will Close Following Lead Candidate’s Disappointing Phase II Results - BioSpace
What drives X4 Pharmaceuticals Inc stock pricePrice Momentum Alerts & Free Trading Signals to Sharpen Your Edge - earlytimes.in
4,485 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Calamos Advisors LLC - MarketBeat
More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals
Short Interest in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Grows By 27.1% - Defense World
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness - PR Newswire
Short Covering: Why X4 Pharmaceuticals Inc 48Q0 stock is a strong buy callJuly 2025 Analyst Calls & Risk Controlled Daily Trade Plans - moha.gov.vn
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2024 Earnings Call Transcript - MSN
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Cwm LLC - MarketBeat
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Rice Hall James & Associates LLC - MarketBeat
174,077 Shares in Crinetics Pharmaceuticals, Inc. $CRNX Purchased by Rice Hall James & Associates LLC - MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross? - Finviz
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon - simplywall.st
Risks To Shareholder Returns Are Elevated At These Prices For X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - 富途牛牛
Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4 - York Dispatch
IndMoney and Federal Bank Savings AccountBull Market Opportunities & Subscribe for Free Weekly Winners - Bollywood Helpline
Will X4 Pharmaceuticals Inc. (48Q0) stock boost dividends further2025 Price Targets & Long Hold Capital Preservation Plans - Улправда
Will X4 Pharmaceuticals Inc. stock continue upward momentumEarnings Trend Report & Safe Entry Trade Signal Reports - Улправда
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Thrivent Financial for Lutherans - MarketBeat
Will X4 Pharmaceuticals Inc. stock deliver long term returns2025 Price Targets & Free Community Supported Trade Ideas - Улправда
Can X4 Pharmaceuticals Inc. stock sustain institutional interestMarket Performance Report & Risk Controlled Stock Pick Alerts - Улправда
Can X4 Pharmaceuticals Inc. stock sustain market leadership2025 Biggest Moves & Advanced Swing Trade Entry Alerts - DonanımHaber
Day Trade: Can X4 Pharmaceuticals Inc. stock sustain market leadershipQuarterly Market Summary & Daily Stock Momentum Reports - DonanımHaber
Institution Moves: Can X4 Pharmaceuticals Inc. stock outperform in 2025 bull marketMarket Growth Report & Risk Managed Investment Strategies - DonanımHaber
Can X4 Pharmaceuticals Inc. stock outperform in 2025 bull marketTrade Entry Report & Capital Efficiency Focused Strategies - DonanımHaber
Pfizer Inc. | Pharmaceuticals, Vaccines & Company History | Britannica Money - Encyclopedia Britannica
Merger Talk: Is X4 Pharmaceuticals Inc. stock supported by strong fundamentals2025 Market Trends & Reliable Price Action Trade Plans - Улправда
• Position Sizing: Never all in — always size by riskInflation Impact on Stocks & Explosive Capital Gains - Bollywood Helpline
InMed Pharmaceuticals (INM) reports senior VP employee option expiration - Stock Titan
Weekly Analysts’ Ratings Changes for X4 Pharmaceuticals (XFOR) - Defense World
Aug Opening: Will X4 Pharmaceuticals Inc. stock deliver long term returns2025 Technical Overview & Verified Chart Pattern Trade Signals - moha.gov.vn
Bain Capital Life Sciences Investors LLC Sells 16,351,925 Shares of X4 Pharmaceuticals, Inc. $XFOR - MarketBeat
X4 Pharmaceuticals, Inc. $XFOR Shares Sold by Acorn Capital Advisors LLC - MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome - Markets Financial Content
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
X4 PharmaSeizing Rare Opportunities, Not Acting On A Whim - RTTNews
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Does X4 Pharmaceuticals Inc (XFOR) offer a good opportunity for investors? - setenews.com
One Peninsula drugmaker to buy another for up to $820 million around drug cut by Novartis - The Business Journals
X4 Pharmaceuticals, Inc. $XFOR Shares Sold by Pale Fire Capital SE - MarketBeat
Tracking the Evolving Narrative for X4 Pharmaceuticals After Financing and Restructuring Moves - Yahoo Finance
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease - Business Wire
Blood pressure drug recalled for possible cross-contamination - USA Today
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
28.63%
자본화:
|
볼륨(24시간):